title: Early treatment intensification with escalated BEACOPP in patients with Hodgkins lymphoma not responding to ABVD therapy.
authors.affiliation: Gdynia Oncology Center , Gdynia , Poland.
authors.forename: Iwona
authors.initials: I
authors.lastname: Danielewicz
authors.forename: Bogdan
authors.initials: B
authors.lastname: Małkowski
authors.forename: Renata
authors.initials: R
authors.lastname: Zaucha
authors.forename: Marta
authors.initials: M
authors.lastname: Zalewska
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Leśniewski-Kmak
authors.forename: Jan Maciej
authors.initials: JM
authors.lastname: Zaucha
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone